901227381639238722518816178790122738163923872251881617878161787816178700000001477845--12-312023Q3false0081639238163923NYSENon-accelerated Filer816392390122731.630.793.902.160.0001P10Y1.630.793.902.160810057081639230.930.792.722.1600014778452022-01-012022-12-310001477845us-gaap:CommonStockMember2023-01-012023-03-310001477845us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001477845us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001477845us-gaap:CommonStockMember2022-01-012022-03-310001477845us-gaap:CommonStockMember2023-04-012023-06-300001477845us-gaap:RetainedEarningsMember2023-09-300001477845us-gaap:AdditionalPaidInCapitalMember2023-09-300001477845us-gaap:RetainedEarningsMember2023-06-300001477845us-gaap:AdditionalPaidInCapitalMember2023-06-3000014778452023-06-300001477845us-gaap:RetainedEarningsMember2023-03-310001477845us-gaap:AdditionalPaidInCapitalMember2023-03-3100014778452023-03-310001477845us-gaap:RetainedEarningsMember2022-12-310001477845us-gaap:AdditionalPaidInCapitalMember2022-12-310001477845us-gaap:RetainedEarningsMember2022-09-300001477845us-gaap:AdditionalPaidInCapitalMember2022-09-300001477845us-gaap:RetainedEarningsMember2022-06-300001477845us-gaap:AdditionalPaidInCapitalMember2022-06-3000014778452022-06-300001477845us-gaap:RetainedEarningsMember2022-03-310001477845us-gaap:AdditionalPaidInCapitalMember2022-03-3100014778452022-03-310001477845us-gaap:RetainedEarningsMember2021-12-310001477845us-gaap:AdditionalPaidInCapitalMember2021-12-310001477845us-gaap:CommonStockMember2023-09-300001477845us-gaap:CommonStockMember2023-06-300001477845us-gaap:CommonStockMember2023-03-310001477845us-gaap:CommonStockMember2022-12-310001477845us-gaap:CommonStockMember2022-09-300001477845us-gaap:CommonStockMember2022-06-300001477845us-gaap:CommonStockMember2022-03-310001477845us-gaap:CommonStockMember2021-12-310001477845us-gaap:EmployeeStockOptionMember2023-09-300001477845us-gaap:EmployeeStockOptionMember2022-12-310001477845us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001477845us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001477845anvs:PreviousPlansMember2023-09-300001477845anvs:EquityIncentivePlan2019Member2023-09-300001477845anvs:EquityIncentivePlan2019Member2021-06-010001477845anvs:EquityIncentivePlan2019Member2021-05-310001477845srt:WeightedAverageMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300001477845us-gaap:EmployeeStockOptionMemberanvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember2023-01-012023-09-300001477845us-gaap:EmployeeStockOptionMemberanvs:QuarterlyInstallmentVestingMember2023-01-012023-09-300001477845us-gaap:PrivatePlacementMember2023-04-070001477845anvs:BankOfAmericaAndThinkEquityLlcSalesAgreementMember2023-04-040001477845srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberanvs:ErrorCorrectionsDueToExpensesRecordedInQ32022Member2022-07-012022-09-300001477845anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember2022-07-012022-09-300001477845anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember2022-01-012022-09-300001477845us-gaap:RetainedEarningsMember2023-07-012023-09-300001477845us-gaap:RetainedEarningsMember2023-04-012023-06-300001477845us-gaap:RetainedEarningsMember2023-01-012023-03-310001477845us-gaap:RetainedEarningsMember2022-07-012022-09-300001477845us-gaap:RetainedEarningsMember2022-04-012022-06-300001477845us-gaap:RetainedEarningsMember2022-01-012022-03-310001477845srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-07-012022-09-300001477845srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-01-012022-09-300001477845srt:ScenarioPreviouslyReportedMember2022-07-012022-09-300001477845srt:ScenarioPreviouslyReportedMember2022-01-012022-09-300001477845srt:ScenarioPreviouslyReportedMember2021-12-3100014778452021-12-310001477845us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001477845us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001477845us-gaap:WarrantMember2023-01-012023-09-300001477845us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001477845us-gaap:WarrantMember2022-01-012022-09-300001477845us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001477845us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001477845us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001477845us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001477845us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001477845us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001477845us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001477845us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001477845us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001477845us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001477845us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000014778452023-04-012023-06-300001477845us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100014778452023-01-012023-03-310001477845us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001477845us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000014778452022-04-012022-06-300001477845us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100014778452022-01-012022-03-3100014778452023-11-060001477845srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMemberanvs:ErrorCorrectionsDueToExpensesRecordedInQ32022Member2022-09-300001477845srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-09-300001477845anvs:TimingOfAccrualsForResearchAndDevelopmentExpensesMember2022-09-300001477845anvs:UnderwritersWarrantsMember2020-01-310001477845us-gaap:SubsequentEventMemberanvs:UnderwritingAgreementWithCanaccordGenuityLlcMember2023-10-312023-10-310001477845srt:ExecutiveOfficerMember2023-09-300001477845us-gaap:PrivatePlacementMember2023-04-072023-04-070001477845anvs:BankOfAmericaAndThinkEquityLlcSalesAgreementMember2023-04-042023-04-0400014778452023-07-012023-09-3000014778452023-01-012023-09-3000014778452022-07-012022-09-3000014778452022-01-012022-09-300001477845us-gaap:SubsequentEventMemberanvs:UnderwritingAgreementWithCanaccordGenuityLlcMember2023-10-310001477845anvs:AtMarketEquityOfferingMember2023-03-3100014778452023-09-3000014778452022-12-310001477845srt:ScenarioPreviouslyReportedMember2022-09-3000014778452022-09-30iso4217:USDxbrli:sharesanvs:itemanvs:Votexbrli:pureanvs:Diso4217:USDxbrli:shares
NYSENon-accelerated Filer00000001477845--12-312024Q1falsefalsefalsefalsefalse000.000110519933110112990001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2024-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2024-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2024-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2024-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputConversionPriceMember2024-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberanvs:MeasurementInputSuccessRateMember2024-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2023-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2023-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2023-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2023-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputConversionPriceMember2023-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberanvs:MeasurementInputSuccessRateMember2023-12-3100014778452023-01-012023-12-310001477845us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001477845us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001477845us-gaap:CommonStockMember2023-01-012023-03-310001477845us-gaap:SubsequentEventMemberanvs:CommonStockPurchaseAgreementMember2024-05-012024-05-310001477845us-gaap:RetainedEarningsMember2024-03-310001477845us-gaap:AdditionalPaidInCapitalMember2024-03-310001477845us-gaap:RetainedEarningsMember2023-12-310001477845us-gaap:AdditionalPaidInCapitalMember2023-12-310001477845us-gaap:RetainedEarningsMember2023-03-310001477845us-gaap:AdditionalPaidInCapitalMember2023-03-310001477845us-gaap:RetainedEarningsMember2022-12-310001477845us-gaap:AdditionalPaidInCapitalMember2022-12-310001477845us-gaap:PrivatePlacementMember2024-03-210001477845us-gaap:PrivatePlacementMember2024-03-150001477845us-gaap:CommonStockMember2024-03-310001477845us-gaap:CommonStockMember2023-12-310001477845us-gaap:CommonStockMember2023-03-310001477845us-gaap:CommonStockMember2022-12-310001477845us-gaap:EmployeeStockOptionMember2024-03-310001477845us-gaap:EmployeeStockOptionMember2023-12-310001477845anvs:PreviousPlansMember2024-03-310001477845anvs:EquityIncentivePlan2019Member2024-03-310001477845anvs:EquityIncentivePlan2019Member2021-06-010001477845anvs:EquityIncentivePlan2019Member2021-05-310001477845anvs:November2023EquityOfferingAndWarrantIssuanceMember2023-10-312023-10-310001477845us-gaap:RetainedEarningsMember2024-01-012024-03-310001477845us-gaap:RetainedEarningsMember2023-01-012023-03-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310001477845anvs:November2023EquityOfferingAndWarrantIssuanceMember2024-03-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001477845anvs:November2023EquityOfferingAndWarrantIssuanceMember2023-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMember2023-12-310001477845anvs:WarrantsClassifiedAsEquityMember2023-12-310001477845anvs:WarrantsClassifiedAsEquityMember2024-03-310001477845anvs:November2023EquityOfferingAndWarrantIssuanceMember2023-10-3100014778452023-03-3100014778452022-12-310001477845us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310001477845us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310001477845us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001477845us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001477845us-gaap:WarrantMember2024-01-012024-03-310001477845us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001477845us-gaap:WarrantMember2023-01-012023-03-310001477845us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001477845us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001477845us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001477845us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001477845us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001477845us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100014778452023-01-012023-03-3100014778452024-05-090001477845us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001477845us-gaap:CommonStockMember2024-01-012024-03-310001477845anvs:WarrantsClassifiedAsEquityMember2020-01-310001477845anvs:FormerChiefFinancialOfficerMember2024-04-300001477845srt:ExecutiveOfficerMember2024-03-310001477845anvs:November2023EquityOfferingAndWarrantIssuanceMember2024-01-012024-03-310001477845us-gaap:PrivatePlacementMember2024-03-212024-03-210001477845us-gaap:PrivatePlacementMember2024-03-152024-03-1500014778452024-01-012024-03-310001477845anvs:November2023EquityOfferingAndWarrantIssuanceMember2024-01-022024-01-020001477845anvs:WarrantsClassifiedAsLiabilitiesMember2024-01-012024-03-310001477845us-gaap:SubsequentEventMemberanvs:CommonStockPurchaseAgreementMember2024-04-250001477845us-gaap:SubsequentEventMemberanvs:CommonStockPurchaseAgreementMember2024-04-252024-04-250001477845anvs:WarrantsClassifiedAsEquityMember2024-01-012024-03-310001477845anvs:WarrantsClassifiedAsEquityMember2023-01-012023-03-310001477845anvs:WarrantsClassifiedAsLiabilitiesMember2024-03-3100014778452024-03-3100014778452023-12-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesanvs:itemanvs:Votexbrli:pureanvs:D

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

| | |
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

FOR THE QUARTERLY PERIOD ENDED March 31, 2024

OR

| | |
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

COMMISSION FILE NUMBER 001-39202

Annovis Bio, Inc.

(Exact name of registrant as specified in its charter)

| Delaware | | 26-2540421 |
| (State or other jurisdiction of | | (I.R.S. Employer |
| incorporation or organization) | | Identification No.) |

101 Lindenwood Drive, Suite 225

Malvern, PA 19355

(Address of registrant's principal executive offices)

(484) 875-3192

Registrant's telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

| Title of Each Class | | Trading Symbol | | Name of Each Exchange on Which Registered |
| Common Stock, par value $0.0001 per share | | ANVS | | New York Stock Exchange |

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

| Large accelerated filer | ☐ | | Accelerated filer | ☐ |
| | | | | |
| Non-accelerated filer | ☒ | | Smaller reporting company | ☒ |
| | | | | |
| Emerging growth company | ☒ | | | |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No.

The number of outstanding shares of the registrant's common stock as of May 9, 2024 was: 11,171,480

Table of Contents

ANNOVIS BIO, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED MARCH 31, 2024

| PART I - FINANCIAL INFORMATION | | Page |
| | | | |
| | | | |
| Item 1. | Financial Statements | | 3 |
| | | | |
| | Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023 | | 3 |
| | | | |
| | Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2023 and 2022 (Unaudited) | | 4 |
| | Statements of Operations for the Three Months Ended March 31, 2024 and 2023 (Unaudited) | | 4 |
| | | | |
| | Statements of Changes in Stockholders' (Deficit) Equity for the Three Months Ended March 31, 2024 and 2023 (Unaudited) | | 5 | Equity for the Three and Nine Months Ended September 30, 2023 and 2022 (Unaudited) | | 5 |
| | | | |
| | Statements of Cash Flows for the Nine Months Ended September 30, 2023 and 2022 (Unaudited) | | 6 |Three Months Ended March, 2024 and 2023 (Unaudited) | | 6 |
| | | | |
| | Notes to Financial Statements (Unaudited) | | 7 |
| | | | |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | | 18 |
| | | | |
| Item 3. | Quantitative and Qualitative Disclosure About Market Risk | | 23 |
| | | | |
| Item 4. | Controls and Procedures | | 23 |
| | | | |
| | | | |
| PART II - OTHER INFORMATION | | |
| | | | |
| | | | |
| Item 1. | Legal Proceedings | | 24 |
| | | | |
| Item 1A. | Risk Factors | | 24 |
| | | | |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | | 24 |
| | | | |
| Item 3. | Defaults Upon Senior Securities | | 24 |
| | | | |
| Item 4. | Mine Safety Disclosures | | 24 |
| | | | |
| Item 5. | Other Information | | 24 |
| | | | |
| Item 6. | Exhibits | | 25 |
| | | | |
| | Signatures | | 26 |

2

Table of Contents

EXPLANATORY NOTE

As disclosed in our Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 31, 2023 (the "Filing Date" and "Form 10-K"), Annovis Bio, Inc. ("Annovis," the "Company," "our," "us" and "we") restated (the "Restatement") our previously issued (i) unaudited condensed balance sheets as of March 31, 2022, June 30, 2022 and September 30, 2022, (ii) unaudited condensed statements of operations and comprehensive loss for the three months ended March 31, 2022, three and six months ended June 30, 2022, and three and nine months ended September 30, 2022, and (iii) unaudited condensed statements of cash flows for the three months ended March 31, 2022, six months ended June 30, 2022 and nine months ended September 30, 2022, in each of the Quarterly Reports on Form 10- Q for the quarterly periods ended March 31, 2022, June 30, 2022 and September 30, 2022.

See Note 12 - Restatement of Previously Issued Unaudited Condensed Financial Statements, to the Financial Statements in the Form 10-K for additional information related to the restatement and additional information related to the restatement of the Condensed Financial Statements for the three and nine months ended September 30, 2022.

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

Annovis Bio, Inc.

Balance Sheets

(Unaudited)

| | | | | | | | |
| | | March 31, | | December 31, | |
| | | 2024 | | 2023 |
| | | | | | | ||
| Assets | | | | | | | |
| Current assets: | | | | | | ||
| Cash and cash equivalents | | $ | 3,136,968 | | $ | 5,754,720 |
| Prepaid expenses and other current assets | | | 4,676,327 | | | 4,453,544 |
| Total current assets | | | 10,223,106 | | | 36,022,069 | |
| Total current assets | | | 7,813,295 | | | 10,208,264 |
| Total assets | | $ | 10,223,106 | | $ | 36,022,069 | |
| Total assets | | $ | 7,813,295 | | $ | 10,208,264 |
| Liabilities and Stockholders' Deficit | | | | | | ||
| Current liabilities: | | | | | | | |
| Accounts payable | | $ | 1,926,397 | | $ | 3,961,254 | |
| Accounts payable | | $ | 4,106,832 | | $ | 1,292,837 |
| Accrued expenses | | | 1,638,499 | | | 3,737,285 | |
| Accrued expenses | | | 763,183 | | | 2,986,273 |
| Total current liabilities | | | 3,564,896 | | |7,698,539 | | 4,870,015 | | | 4,279,110 |
| Warrant liability | | | 6,297,308 | | | 13,680,000 |

| Total liabilities | | | 3,564,896 | | | 7,698,539 | |
| Total liabilities | | | 11,167,323 | | | 17,959,110 |
| Commitments and contingencies (Note 6) | | | | | | |
| Stockholders' (deficit): | | | | | | ||
| Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding | | | - | | | - | |
| Common stock - $0.0001 par value, 70,000,000 and 35,000,000shares authorized and 9,012,273 and 8,163,923 70,000,000 shares authorized and 11,011,299 and 10,519,933 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | | | 1,101 | | | 1,052 |
| Additional paid-in capital | | | 107,970,905 | | | 102,507,189 |
| Accumulated deficit | | | (88,045,693) | | | (54,054,774) | |
| Accumulated deficit | | | (111,326,034) | | | (110,259,087) |
| Total stockholders' equity | | | 6,658,210 | | | 28,323,530 | |
| Total stockholders' (deficit) | | | (3,354,028) | | | (7,750,846) |
| Total liabilities and stockholders' equity | | $ | 10,223,106 | | $ | 36,022,069 | |deficit | | $ | 7,813,295 | | $ | 10,208,264 |

See accompanying notes to financial statements.

3

Table of Contents

Annovis Bio, Inc.

Statements of Operationsand Comprehensive Loss

(Unaudited)

| | | | | | | |
| | | Three Months Ended || Nine Months Ended | |
| | | September 30, | | September 30, | |
| | | March 31, |
| | | 2023 | | 2022 | | 2023 | | 2022 | |
| | | 2024 | | 2023 |
| Operating expenses: | | | | | | || | | | | | |
| Research and development | | $ | 13,837,650 | | $ | 4,123,538 | | $ | 29,885,874 | | $ | 10,307,142 | |6,514,920 | | $ | 7,786,056 |
| General and administrative | | | 1,025,621 | | | 2,361,299 | | | 4,706,813 | | | 7,403,817 | |1,294,887 | | | 2,183,660 |
| Total operating expenses | | | 14,863,271 | | | 6,484,837 | | | 34,592,687 | | | 17,710,959 | |7,809,807 | | | 9,969,716 |
| Operating loss | | | (14,863,271) | | | (6,484,837) | | | (34,592,687) | | | (17,710,959) | |
| Operating loss | | | (7,809,807) | | | (9,969,716) |
| Other income: | | | | | | |
| Interest income net | | | 146,655 | | | 52,886 || | 601,768 | | | 108,559 | |
| Interest income | | | 44,168 | | | 232,535 |
| Change in fair value of warrants | | | 6,698,692 | | | - |

| Total other income | | | 146,655 | | | 52,886 | | | 601,768 | | | 108,559 | |
| Total other income | | | 6,742,860 | | | 232,535 |
| Net loss before income taxes | | | (14,716,616) | | | (6,431,951) | | | (33,990,919) | | | (17,602,400) | |(1,066,947) | | | (9,737,181) |
| Income tax expense (benefit) | | | - | | | - |
| Net loss | | $ | (1,066,947) | | $ | (9,737,181) |
| | - | | | - | |
| Net loss | | $ | (14,716,616) | | $ | (6,431,951) | | $ | (33,990,919) | | $ | (17,602,400) | |
| Net loss per share (Note 9) | | | | | | |
| Basic | | $ | (0.10) | | $ | (1.19) |
| Basic and Diluted loss per common share | | $ | (1.63) | | $ | (0.79) | | $ | (3.90) | | $ | (2.16) | |
| Diluted | | $ | (0.72) | | $ | (1.19) |
| Weighted-average number of common shares used in computing net loss per share | | | | | | |

| Weighted average number of common shares outstanding, Basic and diluted | | | 9,012,273 | | | 8,163,923 | | | 8,722,518 | | | 8,161,787 | |
| Basic | | | 10,625,065 | | | 8,194,990 |
| Diluted | | | 10,824,771 | | | 8,194,990 |


See accompanying notes to financial statements.

4

Table of Contents

Annovis Bio, Inc.

Statements of Changes in Stockholders' (Deficit) Equity

(Unaudited)

| | | | | | | | | | | | | | | |
| | | || | | | Additional | | | | | Total |
| | | Stockholders' (Deficit) Equity |
| | | | | | | | Additional | | Total | | Total |

| | | Common Stock | | Paid-In | | Accumulated | | Stockholders' (Deficit) |
| | | Shares | | Amount | | Capital | | Deficit | | Equity |
| Three and Nine Months Ended September 30, 
| Three Months Ended March 31, 2024 | | | | | | | | | | | | | | |
| Balance, December 31, 2023 | | 10,519,933 | | $ | 1,052 | | $ | 102,507,189 | | $ | (110,259,087) | | $ | (7,750,846) |
| Exercise of common stock warrants | | 60,000 | | | 6 | | | 1,223,994 | | | - | | | 1,224,000 |
| Issuance of common stock, net of issuance costs | | 431,366 | | | 43 | | | 3,874,957 | | | - | | | 3,875,000 |
| Stock-based compensation expense | | - | | | - | | | 364,765 | | | - | | | 364,765 |
| Net loss | | - | | | - | | | - | | | (1,066,947) | | | (1,066,947) |
| Balance, March 31, 2024 | | 11,011,299 | | | 1,101 | | | 107,970,905 | | | (111,326,034) | | | (3,354,028) |
| | | | | | | | | | | | | | | |
| Three Months Ended March 31, 2023 | | | | | | | | | | | | | | |
| Balance, December 31, 2022 | | 8,163,923 | | $ | 816 | | $ | 82,377,488 | | $ | (54,054,774) | | $ | 28,323,530 |
| Exercise of stock options | | 52,755 | | | 6 | | | 7,380 | | | - | | | 7,386 |
| Stock-based compensation expense | | - | | | - | | | 1,542,338 | | | - | | | 1,542,338 |
| Net and comprehensive loss | | - | | | - | | | - | | | (9,737,181) | | | (9,737,181) |
| Balance, March 31, 2023 | | 8,216,678 | | $ | 822 | | $ | 83,927,206 | | $ | (63,791,955) | | $ | 20,136,073 |

| Issuance of common stock, net of issuance costs | | 788,453 | | | 79 | | | 8,571,112 | | | - | | | 8,571,191 |
| Exercise of stock options | | 7,142 | | | 1 | | | 999 | | | - | | | 1,000 |
| Stock-based compensation expense | | - | | | - | | | 1,571,493 | | | - | | | 1,571,493 |
| Net and comprehensive loss | | - | | | - | | | - | | | (9,537,122) | | | (9,537,122) |
| Balance, June 30, 2023 | | 9,012,273 | | $ | 902 | | $ | 94,070,810 | | $ | (73,329,077) | | $ | 20,742,635 |
| Stock-based compensation expense | | - | | | - | | | 632,191 | | | - | | | 632,191 |
| Net and comprehensive loss | | - | | | - | | | - | | | (14,716,616) | | | (14,716,616) |
| Balance, September 30, 2023 | | 9,012,273 | | $ | 902 | | $ | 94,703,001 | | $ | (88,045,693) | | $ | 6,658,210 |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Three and Nine Months Ended September 30, 2022 | | | | | | | | | | | | | | |
| Balance, December 31, 2021 | | 8,100,570 | | $ | 810 | | $ | 73,220,361 | | $ | (28,726,207) | | $ | 44,494,964 |
| Exercise of stock options | | 63,353 | | | 6 | | | 4,607 | | | - | | | 4,613 |
| Stock-based compensation expense | | - | | | - | | | 3,434,944 | | | - | | | 3,434,944 |
| Net and comprehensive loss | | - | | | - | | | - | | | (5,234,063) | | | (5,234,063) |
| Balance, March 31, 2022 | | 8,163,923 | | $ | 816 | | $ | 76,659,912 | | $ | (33,960,270) | | $ | 42,700,458 |
| Stock-based compensation expense | | - | | | - | | | 1,903,761 | | | - | | | 1,903,761 |
| Net and comprehensive loss | | - | | | - | | | - | | | (5,936,386) | | | (5,936,386) |
| Balance, June 30, 2022 | | 8,163,923 | | $ | 816 | | $ | 78,563,673 | | $ | (39,896,656) | | $ | 38,667,833 |
| Stock-based compensation expense | | - | | | - | | | 2,356,011 | | | - | | | 2,356,011 |
| Net and comprehensive loss | | - | | | - | | | - | | | (6,431,951) | | | (6,431,951) |
| Balance, September 30, 2022 | | 8,163,923 | | $ | 816 | | $ | 80,919,684 | | $ | (46,328,607) | | $ | 34,591,893 |

See accompanying notes to financial statements.

5

Table of Contents

Annovis Bio, Inc.

Statements of Cash Flows

(Unaudited)

| | | | | | | |
| | | Three Months Ended March 31, |
| | | 2024 | | 2023 |
| Cash flows from operating activities: | | | | | | |
| Net loss | | $ | (33,990,919) | | $ | (17,602,400) |
| Net loss | | $ | (1,066,947) | | $ | (9,737,181) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | |
| Stock-based compensation expense | | | 364,765 | | | 1,542,338 |
| Change in fair value of warrants | | | (6,698,692) | | | - |
| Changes in operating assets and liabilities: | | | | | | |
| Prepaid expenses and other current assets | | | (222,783) | | | (1,144,221) |
| Accounts payable | | | (2,034,857) | | | 1,157,631 |
| Accounts payable | | | 2,813,995 | | | 191,686 |
| Accrued expenses | | | (2,098,786) | | | (137,610) |
| Accrued expenses | | | (2,223,090) | | | (2,478,935) |
| Net cash used in operating activities | | | (7,032,752) | | | (11,626,313) |
| Cash flows from financing activities: | | | | | | |
| Proceeds from issuance of common stock, net | | | 3,875,000 | | | - |
| Proceeds from exercise of warrants | | | 540,000 | | | - |
of issuance costs | | | 8,571,191 | | | - |
| Proceeds from exercise of stock options | | | - | | | 7,386 |
| Net cash provided by financing activities | | | 4,415,000 | | | 7,386 |
| Net decrease in cash and cash equivalents | | | (2,617,752) | | | (11,618,927) |
| Cash and cash equivalents, beginning of year | | | 28,377,693 | | | 45,686,014 |period | | | 5,754,720 | | | 28,377,693 |
| Cash and cash equivalents, end of period | | $ | 3,136,968 | | $ | 16,758,766 |

See accompanying notes to financial statements.

6

Table of Contents

Annovis Bio, Inc.

Notes to Financial Statements

(Unaudited)

(1) Nature of Business, Going Concern and Management's Plan

Annovis Bio, Inc. (the "Company" or "Annovis") was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration, such as Alzheimer's disease ("AD") and Parkinson's disease ("PD"). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins, which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company's lead product candidate, Buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins, thereby impeding the toxic cascade. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. The Company has shown in its clinical and pre-clinical studies that Buntanetap lowered neurotoxic protein levels, leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved function.

Going Concern

Since its founding, the Company has been engaged in organizational activities, including raising capital, as well as research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company's research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company's future operations are dependent on the success of the Company's efforts to raise additional capital.

The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company's primary source of capital has been the issuance of equity securities. The Company's common stock.trades on the New York Stock Exchange under the ticker symbol "ANVS"common stock and warrants to purchase common stock.

Since the Company's inception, the Company has incurred losses and negative cash flows from operations. At March 31, 2024, the Company had cash and cash equivalents of $3.1 million and an accumulated deficit of $111.3 million. The Company's net loss was $1.1 million and $9.7 million for the three months ended March 31, 2024 and 2023, respectively. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements-Going Concern, or ASC 205-40, which requires Management to assess the Company's ability to continue as a going concern for one year after the date its financial statements are issued. The Company expects that its existing balance of cash and cash equivalents as of March 31, 2024, combined with cash raised in connection with its ELOC financings, is not sufficient to fund operations for the period through one year after the date of this filing and therefore Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Management's plans to mitigate this risk include raising additional capital through equity financings, debt or other potential alternatives. Management's plans may also include the deferral of certain operating expenses unless and until additional capital is received.


At present, the Company lacks sufficient capital on hand to fund its operations for the next 12 months and will need to raise additional capital to ensure its continuity of operations. The Company believes that its current cash and cash equivalents together with the public offering that closed on November 2, 2023 (see Note 12 - Subsequent Events) will be sufficient to fund its operations into the first quarter of 2024, including its ongoing Phase 2/3 AD Trial and its ongoing Phase 3 PD Trial. the Company plans to raise additional capital to complete the development and commercialization of its product candidates through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives.
However, there can be no assurance that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. The failure to obtain sufficient capital on acceptable terms when needed would have a material adverse effect on the Company's business, results of operations, and financial condition. Accordingly, Management has concluded that substantial doubt. exists with respect to the Company's ability to continue as a going concern for one year after the date that these financial statements are issued.raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, Management concluded that such plans do not alleviate the aforementioned substantial doubt. If the Company is unable to raise sufficient additional capital or defer sufficient operating expenses, the Company may be compelled to reduce the scope of its operations.

7

Table of Contents

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

7

Table of Contents

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation of Interim Unaudited Financial Statements

The accompanying interim financial statements of Annovis Bio, Inc. should be read in conjunction with the audited financial statements and notes thereto included in the Company's 2023 Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 31, 2023. In the Company's Annual Report on Form 10-K for the year ended December 31, 2022, the Company restated (i) unaudited condensed balance sheets as of March 31, 2022, June 30, 2022 and September 30, 2022, (ii) unaudited condensed statements of operations and comprehensive loss for the three months ended March 31, 2022, three and six months ended June 30, 2022, and three and nine months ended September 30, 2022, and (iii) unaudited condensed statements of cash flows for the three months ended March 31, 2022, six months ended June 30, 2022 and nine months ended September 30, 2022, in each of the Quarterly Reports on Form 10- Q for the quarterly periods ended March 31, 2022, June 30, 2022 and September 30, 2022. The restatement resulted from the Company's prior accounting for payments for research and development expenses and recognition of expenses. Accordingly, certain amounts for the three and nine months ended September 30, 2022 presented herein reflect the restated amounts.

29, 2024. The interim financial statements included herein are unaudited. In the opinion of Management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at March 31, 2024, its results of operations for the three and nine months ended September 30, 2023 and 2022 months ended March 31, 2024 and 2023 and its cash flows for the three month periods ended March 31, 2024 and 2023. The interim results of operations are not necessarily indicative of the results to be expected for a full year or any future period. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") and the rules and regulations of the SEC. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB"). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.

Significant items subject to such estimates and assumptions include stock-based compensation expense, and prepaid expenses and accrued liabilities, that are measured based on progress toward completion of research and development projects. the accounting and fair value of equity instruments, common stock warrant liabilities, as well as accounting for research and development contracts, including clinical trial accruals. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

(c) Basic and Diluted Net (Loss) per Share

Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect.

8

Table of Contents

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds, could have a significant adverse effect on the Company's financial condition, results of operations and cash flows.

8

Table of Contents

(e) Issuance Costs Associated with Equity Issuances

Issuance costs incurred in connection with the Company's equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.

(f) Fair Value of Financial Instruments

The Company's financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value the recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.
The fair value of the Company's assets and liabilities, which qualify as financial instruments under FASB ASC Topic 820, "Fair Value Measurements," equals or approximates the carrying amounts represented in the balance sheets, primarily due to their short-term nature, except for the derivative warrant liabilities (see Note 3).

(g) Common Stock Warrants

On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share ("Canaccord Warrants"). The warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company's control or not deemed to be indexed to the Company's stock. The warrant liabilities are recorded at fair value regardless of the timing of the redemption feature, the redemption price, or the likelihood of redemption. These warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise, expiration, or other settlement of the warrants. The warrants are classified as Level 3 liabilities.

(h) Research and Development

Research and development costs are either expensed as incurred or recorded separately as a prepaid asset, and the expense recognized when the service is performed and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company's contracts with its vendors and are realized in the ordinary course of business.

(i) Stock-Based Compensation

The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation-Stock Compensation ("ASC 718"). The Company has issued stock-based compensation awards including stock options. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the financial statements based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. The Company recognizes forfeitures as they occur.
stock-based compensation cost is measured at The grant date based on the fair value of The award and is generally recognized as expense on a straight-line basis over the requisite service period which is generally the vesting period. The Company also has options outstanding with a


Expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock options have a contractual term of 10 years. Expense for stock-based compensation awards with performance-based vesting conditions for which the Company recognizes expense based on the estimated probability of achievement of the performance metrics over the contractual term of the option. Forfeitures are recognized in compensation expense in the period when they occur.is only recognized when the performance-based vesting condition is deemed probable to occur. Expense related to stock-based compensation awards are recorded to research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award.

9

Table of Contents

Estimating the fair value of stock options requires the input of subjective the Company uses the Black-Scholes option pricing model to value its option awards which requires the use of assumptions, including the expected life of the option, and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model represent Management's best estimates and involve a number of variables, uncertainties, assumptions, and the application of Management's judgment, as a result, If factors change, and management uses different assumptions, they are inherently subjective. If any assumptions change, the Company's stock-based compensation expense could be materially different in the future.

The assumptions used in the Company's Black-Scholes option-pricing model for stock options are as follows:

Expected Term. As Annovis does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee stock options subject to service-based vesting conditions is determined using the "simplified" method, as prescribed in SEC's Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock option.
upon exercise of stock options the Company issues shares first from Treasury stock.if available, then from authorized but unissued shares.


Expected Volatility. The expected volatility is based on historical volatilities of Annovis and similar entities within the Company's industry for periods commensurate with the assumed expected term.

Risk-Free Interest Rate. The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.

Expected Dividends. The expected dividend yield is 0% because Annovis has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.

(j) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation

9

Table of Contents

allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2023 and December 31, 2022, the Company has recorded March 31, 2024 and December 31, 2023, the Company had a full valuation allowance against its deferred tax assets.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at March 31, 2024 or December 31, 2023.

(k) Recent Accounting Pronouncements

There are No. recent accounting pronouncements that would have a significant impact on the Company's financial statements.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not yet determined the impact ASU 2023-09 may have on the Company's financial statement disclosures.

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to

10

Table of Contents

transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1-Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2-Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3-Valuations based on unobservable inputs and models that are supported by little or no market activity.

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023:

| | | | | | | | | | | | | |
| | | | | | Fair Value Measurement at |
| | | | | | March 31, 2024 |
| | | Carrying Value | | Level 1 | | Level 2 | | Level 3 |
| Assets: | | | | | | | | | | | | |
| Cash equivalents | | $ | 472,898 | | $ | 472,898 | | $ | - | | $ | - |
| Cash equivalents | | $ | 3,873,159 | | $ | 3,873,159 | | $ | - | | $ | - |
| Total assets measured and recorded at fair value | | $ | 472,898 | | $ | 472,898 | | $ | - | | $ | - |
| Liabilities: | | | | | | | | | | | | |
| Warrant liability | | $ | 6,297,308 | | $ | - | | $ | - | | $ | 6,297,308 |
| Total liabilities measured and recorded at fair value | | $ | 6,297,308 | | $ | - | | $ | - | | $ | 6,297,308 |

| | | | | | | | | | | | | |
| | | | | | Fair Value Measurement at |
| | | | | | December 31, 2023 |
| | | Carrying Value | | Level 1 | | Level 2 | | Level 3 |
| Assets: | | | | | | | | | | | | |
| Cash equivalents | | $ | 5,136,677 | | $ | 5,136,677 | | $ | - | | $ | - |
| Cash equivalents | | $ | 26,001,934 | | $ | 26,001,934 | | $ | - | | $ | - |
| Total assets measured and recorded at fair value | | $ | 5,136,677 | | $ | 5,136,677 | | $ | - | | $ | - |
| Liabilities: | | | | | | | | | | | | |
| Warrant liability | | $ | 13,680,000 | | $ | - | | $ | - | | $ | 13,680,000 |
| Total liabilities measured and recorded at fair value | | $ | 13,680,000 | | $ | - | | $ | - | | $ | 13,680,000 |

The Company did not transfer any financial instruments into or out of Level 3 classification, during the three months ended March 31, 2024 and 2023.

The common stock warrants issued in connection with the Company's equity raise in November 2023 (Canaccord Warrants) were classified as liabilities at the time of issuance due to certain cash settlement adjustment features that are outside of the Company's control or not deemed to be indexed to the Company's stock. The warrant liability is remeasured each reporting period with the change in fair value recorded to other income (expense) in the statement of operations until the warrants are exercised, expired, reclassified, or otherwise settled. The fair value of the warrant liability was estimated using a Monte Carlo simulation model.

The estimated fair value of the Canaccord Warrants is determined using Level 3 inputs. Inherent in a Monte Carlo simulation model with the volatility calculated by back solving in a Monte Carlo simulation are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and other inputs. The Company estimates the volatility of its warrants based on implied volatility from the Company's traded warrants. The risk-free interest rate is

11

Table of Contents

based on the market yield of U.S. Treasuries over a tenor commensurate with the remaining term to expiration. Any changes in these assumptions can change the valuation significantly.

The following table provides quantitative information regarding Level 3 fair value measurements inputs as of their measurement dates:

| | | | | | | | |
| | | March 31, 2024 | | December 31, 2023 | |
| Exercise price | | $ | 9.00 | | $ | 9.00 | |
| Closing stock price | | $ | 11.90 | | $ | 18.70 | |
| Number of warrants | | | 1,140,000 | | | 1,200,000 | |
| Phase 3 data probability of success | | | 60 | % | | 60 | % |
| Volatility | | | 60 | % | | 55 | % |
| Term (time to expiration in years) | | | 4.59 | | | 4.84 | |
| Redemption hurdle price | | $ | 14.25 | | $ | 14.25 | |
| Risk-free rate | | | 4.2 | % | | 3.9 | % |

The Canaccord Warrants were exercisable immediately at an exercise price of $9.00 per unit, and redeemable at the Company's option, in whole or in part, at a redemption price equal to $0.001 per Warrant upon 30 days' prior written notice, at any time after:

| | ● | the Company's public announcement of Positive Topline Data (as defined in the Warrant Agreement) from its Phase 3 in patients with Parkinson's Disease; and |
| | ● | the date on which (a) the closing price of the Company's common stock on the principal exchange or trading facility on which it is then traded has equaled or exceeded $14.25 and (b) the average daily trading value (ADTV) of the Company's common stock is equal to or exceeds $2,000,000, for two consecutive Trading Days. |

The common stock warrants are exercisable immediately and will expire on November 2, 2028, five years from the date of issuance.

(4) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

| | | | | | | | |
| | | March 31, | | December 31, ||
| | | 2024 | | 2023 |
| Prepaid expenses | | $ | 188,490 | | $ | 23,455 |
| Prepaid clinical trial expenses | | | 4,355,425 | | | 4,391,219 |
| Prepaid insurance | | | 126,616 | | | 18,074 |
| Security deposits and other | | | 20,619 | | | 11,238 | |
| Security deposits | | | 5,796 | | | 20,796 |
| | | $ | 3,868,164 | | $ | 7,644,376 | |
| | | $ | 4,676,327 | | $ | 4,453,544 |

(5) Accrued Expenses

Accrued expenses consisted of the following:

| | | | | | | ||
| | | March 31, | | December 31, | |
| | | 2024 | | 2023 |
| Payroll and related benefits | | $ | 264,113 | | $ | 96,848 |
| Accrued professional and clinical fees | | | 499,070 | | | 2,889,425 |
| | | $ | 1,638,499 | | $ | 3,737,285 ||
| | | $ | 763,183 | | $ | 2,986,273 |

12

Table of Contents

(6) Commitments and Contingencies

(a) Research & Development

The Company has entered into contracts with contract research organizations ("CROs") and contract manufacturers ("CMOs") related to the Company's clinical trials. The contracts generally require upfront payments, milestone payments, and pass through cost reimbursement, to be made. While the contracts are cancellable with (written) notice, the Company is obligated for payments for services rendered through the termination date of the project with any applicable CRO/CMO.

(b) Leases

In November 2023, the Company entered into a short-term lease for office space, with an initial term of less than 12 months. Prior to entering into this lease, the Company was leasing its office facilities under a month-to-month short-term lease. Total rental expense, inclusive of both leases was $33,875 and $17,571 for the three months ended March 31, 2024 and 2023, respectively.
the Company leases office space, which is accounted for as a short term lease. Total rental expense, was $23,891 and $16,930 for the three months ended September 30, 2023 and 2022, respectively, and $59,165 and $50,287 for the nine months ended September 30, 2023, and 2022, respectively.

(c) Employment Agreements

The Company has agreements with its executive officers that provide for severance payments to the employee upon termination of the agreement by the Company for any reason other than for cause, death, or disability or by the employee for good reason. The maximum aggregate severance payments under the agreements were approximately $1,307,100 at September 30, 2023.estimated to be $1,340,162 at March 31, 2024.

Effective as of the close of business on April 30, 2024, Henry Hagopian no longer served as the Chief Financial Officer and principal financial officer of the Company. In connection with Mr. Hagopian's departure, the terms of his employment agreement were modified by a separation and general release agreement. Pursuant to this agreement, the maximum aggregate severance payment payable to Mr. Hagopian is $65,500.

(d) Litigation

The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company's liquidity, financial condition and cash flows.

11

Table of Contents

At September 30, 2023,
At March 31, 2024, the Company did not have any pending legal actions.

(7) Stockholders' (Deficit) Equity

(a) Overview

The Company's Amended and Restated Certificate of Incorporation was adopted on January 31, 2020, in conjunction with the closing of the Company's initial public offering (the "IPO") and amended on June 15, 2023 to increase the authorized number of shares. Currently, there are two classes of stock authorized which are designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 72,000,000, each with a par value of $0.0001 per share. Of these shares, 70,000,000 shall be common stock and 2,000,000 shall be preferred stock.

On March 31, 2023, the "Company, entered into an ATM Equity Offering Sales Agreement SM (the "Sales Agreement") with BofA Securities, Inc. ("BofA") and ThinkEquity LLC ("ThinkEquity" and, together with BofA, the "Sales Agents"), as sales agents, pursuant to which the Company may offer and sell, from time to time through the Sales Agents, shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), having an aggregate offering price of up to $50.0 million.
13

On April 4, 2023, the Company delivered written notice to BofA and ThinkEquity to terminate the Sales Agreement, effective April 9, 2023, pursuant to Section 9(a) of the Sales Agreement. The Company is not subject to any termination penalties related to the termination of the Sales Agreement.
Table of Contents


Prior to termination of the Sales Agreement, the Company sold 704,000 shares of Common Stock pursuant to the Sales Agreement at a price of $10.88 per share, for gross proceeds of $7,659,520 before commissions. As a result of the termination of the Sales Agreement, the Company will not offer or sell any additional shares of Common Stock under the Sales Agreement.

In addition, on April 7, 2023, the Company sold 84,453 shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $12.61 per share, for aggregate proceeds of $ 1.06 million.

(b) Common Stock

1. Dividends

Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.

2. Liquidation

Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.

3. Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

12

Table of Contents

(c) Preferred Stock

Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of March 31, 2024 or December 31, 2023.

(d) IPO Warrants

In conjunction with the closing of the Company's Initial Public Offering ("IPO"), the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock ("IPO Warrants") at an exercise price of $7.50 per share, which was 125% of the initial public offering price. The IPO Warrants have a five-year term and were exercisable as of January 29, 2021 and have been classified by the Company as a component of stockholders' equity. As of March 31, 2024 and December 31, 2023, 2,400 of the IPO Warrants were outstanding. No IPO Warrants were exercised during the three or nine months ended September 30, 2023 or 2022.months ended March 31, 2024 or 2023.

(e) November 2023 Equity Offering and Warrant Issuance

On October 31, 2023, the Company completed an underwritten offering with a Canaccord Genuity LLC whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants ("Canaccord Warrants") to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share. The warrants are exercisable immediately on the date of issuance and will expire five years after the date of issuance. The Company received $6.83 million in net cash proceeds after deducting underwriter discount and fees, as well as other third-party costs. The warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company's control or not deemed to be indexed to the Company's stock, respectively.

The following is a roll forward of the Common Stock Warrant Liability from December 31, 2023 to March 31, 2024:

| | | |
| Warrant liability at December 31, 2023 | | 13,680,000 |
| Exercise of 60,000 warrants - January 2, 2024 | | (684,000) |
| Change in fair value of warrant liabilities | | (6,698,692) |
| Warrant liability at March 31, 2024 | | 6,297,308 |

14

Table of Contents

(f) Warrant Summary

As of March 31, 2024, the Company had the following common stock warrants outstanding:

| | | | | | | | | | | | | | | | |
| | | | | Outstanding | | | | | | Outstanding | | Exercise | | |
| | | | | December 31, | | | | Exercised or | | March 31, | | price per | | Expiration |
| | | Classification | | 2023 | | Granted | | Expired | | 2024 | | share | | date |
| IPO Warrants | | Equity | | 2,400 | | - | | - | | 2,400 | | $ | 7.50 | | January 29, 2026 |
| Canaccord Warrants | | Liability | | 1,200,000 | | - | | (60,000) | | 1,140,000 | | $ | 9.00 | | October 31, 2028 |

(g) March 15th Registered Direct Offering ("March RDO Round 1")

On March 15, 2024, the Company entered into a Securities Purchase Agreement with an institutional investor. Pursuant to the terms of the purchase agreement, the Company agreed to issue and sell an aggregate of 114,911 shares of Common Stock at $8.92 per share for aggregate gross proceeds of $1,025,000. Net of offering costs, proceeds from this offering were $925,000.

(h) March 21st Registered Direct Offering ("March RDO Round 2")

On March 21, 2024, Annovis Bio, Inc. the Company entered into a Securities Purchase Agreement with an institutional investor. Pursuant to the terms of the purchase agreement, the Company agreed to issue and sell an aggregate of 316,455 shares of Common Stock at $9.48 per share for aggregate gross proceeds of $3,000,000. Net of offering costs, proceeds from this offering were $2,950,000.

(8) Stock-Based Compensation

The Company's 2019 Equity Incentive Plan (the "2019 Plan") became effective on January 31, 2020, succeeding the Company's previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 to 2,000,000. As of March 31, 2024, 35,545 shares were available for future grants.

Stock-based compensation expense was as follows:

| | | | | | | |
| | | Three Months Ended | | Nine Months Ended |
| | | March 31, |
| | | 2024 | | 2023 |
| General and administrative | | $ | 379,364 | | | 1,627,820 | | $ | 1,792,819 | | | 5,053,502 |235,740 | | $ | 769,102 |
| Research and development | | | 252,827 | | | 728,191 | | | 1,953,203 | | | 2,641,214 |129,025 | | | 773,236 |
| | | $ | 632,191 | | $ | 2,356,011 | | $ | 3,746,022 | | $ | 7,694,716 |
| | | $ | 364,765 | | $ | 1,542,338 |

During the nine months ended September 30, 2023, the Company granted options to purchase 126,883 shares of common stock at a weighted-average exercise price of $13.28 per share to employees, and consultants. Under the grant agreements, 35,178 of the options vested immediately and have a 10-year term. The rest of the options have service based vesting conditions and generally vest in substantially equal quarterly installments over two years and have a 10 year term. The options granted during the nine months ended September 30, 2023 were valued using the Black Scholes option pricing model using the following weighted-average assumptions: (i) expected term of 5.56 years; (ii) risk free interest rate of 3.62%; (iii) expected volatility of 127.5%; and (iv) dividend yield of 0.0%. The weighted-average grant date fair value of options issued by the Company during the three months ended September 30, 2023 was $11.29 per share.
During the three months ended March 31, 2024, the Company did not grant any options to purchase shares of common stock to its executives, its employees, or its Board of Directors.

No Stock options were exercised during the three months ended September 30, 2023 and 2022. Stock options exercised during the nine months ended September 30, 2023 and 2022, were 59,897 and 70,101, respectively. As of September 30, 2023, there were 1,724,328 March 31, 2024 and 2023 were zero and 52,755, respectively. As of March 31, 2024, there were 1,954,774 options outstanding, of which 1,663,045 were vested and exercisable. As of December 31, 2023, there were 1,954,774 options outstanding, of which 1,600,577 were vested and exercisable.

During The nine months ended September 30, 2022, previously issued stock options were modified for an employee who is no longer with the Company. As a result of this modification, $1,219,572 was recognized as stock option modification expense and included in general and administrative expenses on the accompanying statement of operations.
(9) Net Loss Per Share

The Company analyzes the potential dilutive effect of stock options and warrants under the treasury stock method (as applicable), during periods of income, or during periods in which income is recognized related to changes in fair value of its liability-classified securities.


15

Table of Contents

(9) Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per common share:

| | | | | | | |
| | | Three Months Ended |
| | | March 31, |
| | | Three Months Ended | | Nine Months Ended | |
| | | 2024 | | 2023 |
| | | September 30, | | September 30, | |
| Net loss per share - Basic: | | | | | | |
| | | 2023 | | 2022 | | 2023 | | 2022 | |
| Numerator | | | | | | |
| Net loss | | $ | (1,066,947) | | $ | (9,737,181) |
| Numerator | | | | | | || | | | | | |
| Denominator | | | | | | |
| Weighted-average common shares outstanding, basic | | | 10,625,065 | | | 8,194,990 |

| net loss | | $ | (14,716,616) | | $ | (6,431,951) | | $ | (33,990,919) | | $ | (17,602,400) | |
| Basic net loss per common share | | $ | (0.10) | | $ | (1.19) |
| | | | | | | |

| Denominator | | | | | | || | | | | | || Net loss per share - Diluted: | | | | | | |
| Numerator | | | | | | |

| Weighted-average common shares outstanding, basic and diluted | | | 9,012,273 | | | 8,163,923 || | 8,722,518 | | | 8,161,787 | |
| Net loss | | $ | (1,066,947) | | $ | (9,737,181) |
| Less: gain from change in fair value applicable to dilutive liability-classified warrants | | | (6,698,692) | | | - |

| net loss per share basic and diluted | | $ | (1.63) | | $ | (0.79) || $ | (3.90) | | $ | (2.16) | |
| Numerator for diluted net loss per share | | $ | (7,765,639) | | $ | (9,737,181) |
| Denominator | | | | | | |
| Denominator for basic net loss per share | | | 10,625,065 | | | 8,194,990 |

| Plus: Incremental shares underlying "in the money" liability-classified warrants outstanding | | | 199,706 | | | - |
the Company reported a net loss for the three and nine months ended September 30, 2023 and 2022, therefore, the basic and Diluted net loss per share were the same in the respective period because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock
| Denominator for diluted net loss per share | | | 10,824,771 | | | 8,194,990 |
| Diluted net loss per common share | | $ | (0.72) | | $ | (1.19) |

Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted earnings per share for each of the three months ended March 31, 2024 and 2023. Total antidilutive securities that were excluded from the computation of diluted weighted-average shares outstanding were as follows:

| | | | | ||
| | | March 31, |
| | | 2024 | | 2023 |
| Stock options | | 1,724,328 | | 1,657,342 | |
| Stock options | | 1,954,774 | | 1,686,292 |
| Warrants | | 2,400 | | 2,400 ||

(10) Income Taxes

The Company's income tax benefit (expense) was $0 for the three and nine months ended September 30, 2023. and 2022.months ended March 31, 2024 and 2023. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss ("NOL") that would have been recognized in the three and nine months ended September 30, 2023 and 2022 months ended March 31, 2024 and 2023 was offset by changes in the valuation allowance.

Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.

As of March 31, 2024, and December 31, 2023, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company's statements of operations.

(11) Restatement of Previously Issued Unaudited Condensed Financial Statements
(11) Subsequent Events

As disclosed in the Form 10-K filed with the SEC On March 31, 2023, during its preparation of its 2022 audited combined financial statements and notes thereto, the Company concluded that there were material research and development expenses and related balance sheet errors in its previously issued unaudited condensed financial statements for the three and nine months ended September 30, 2022, primarily relating to the timing of payments for research and development expenses and recognition of expenses.
On April 25, 2024, the Company entered into a Common Stock Purchase Agreement (the "ELOC Purchase Agreement") with an Equity Line investor (the "ELOC Purchaser"), whereby the Company may offer and sell, from time

16

Table of Contents

The Company noted the following items were improperly expensed during the three and nine months ended September 30, 2022:
to time at its sole discretion, and whereby the ELOC Purchaser has committed to purchase, up to 2,051,428 shares of shares of the Company's common stock, $0.0001 par value per share (the "Common Stock"), subject to certain limitations. Under the Purchase Agreement, the Company has agreed to issue to the ELOC Purchaser shares of Common Stock with a total value of $375,000 as commitment shares, with 10,181 shares being delivered on the date of the Purchase Agreement and the remaining shares to be delivered on the 90th and 180th day thereafter. Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with the ELOC Purchaser, pursuant to which it agreed to provide the ELOC Purchaser with certain registration rights related to the shares issued under the Purchase Agreement. In May 2024, we have issued approximately 150,000 common shares pursuant to the ELOC Purchase Agreement, resulting in net proceeds of $0.8 million.


● Payments, in the amount of $1,320,321, were improperly recorded in research and development expenses during the three months ended September 30, 2022. These amounts should have been recorded in prepaid expenses and other current assets as of September 30, 2022. Additionally, $130,826 was expensed during the three months ended September 30, 2022 related to the prior quarter restatements.

These errors, including the errors from the six months ended June 30, 2022, in the accounting for research and development expenses resulted in an understatement of prepaid assets and other current assets of $4,631,390 as of September 30, 2022, and an overstatement of operating expenses and net loss of $1,189,495 and $4,631,390 for the three and nine months ended September 30, 2022, respectively.. See Note 12 - Restatement of Previously Issued Unaudited Condensed Financial Statements, to the Financial Statements in the Form 10-K for additional information related to the restatements.

In connection with the filing of this Quarterly Report on Form 10-Q, the Company has restated the accompanying interim Condensed Financial Statements for the three and nine months ended September 30, 2022 to correct for the impact of the misstatements. The applicable notes to the accompanying financial statements have also been corrected to reflect the impact of the restatement. Below, we have presented a reconciliation from the "As Reported" to the "As Restated" amounts for each of our interim Condensed Financial Statements as of and for the three and nine months ended September 30, 2022. The amounts "As Reported" are from the "As Reported" amounts as disclosed in Note 12 - Restatement of Previously Issued Unaudited Condensed Financial Statements (Unaudited) in the Form 10-K.

15

Table of Contents

| | | | | | | | | | |

Additionally, effective as of the close of business on April 30, 2024, our chief financial officer resigned as principal financial officer of the "Company. In connection with his departure from the Company, the Company entered into a Separation Agreement and General Release with the former CFO (the "Separation Agreement"), dated as of April 30, 2024 (the "Separation Date"), pursuant to which the parties have agreed upon the terms of his separation from the Company. Pursuant to the Separation Agreement, the former CFO has agreed to comply with certain confidentiality and cooperation provisions. The Separation Agreement also provides for a customary general release of claims and certain severance benefits, as previously outlined in a Form 8-K dated May 1, 2024.
| | | (unaudited) |
| | | As | | Restatement | | As |
| | | Reported | | Impacts | | Restated |
| Assets | | | | | | | | | |
| Current assets: | | | | | | | | | |
| Cash and cash equivalents | | $ | 31,987,091 | | $ | | | $ | 31,987,091 |
| Prepaid expenses and other current assets | | | 499,947 | | | 4,631,390 | | | 5,131,337 |
| Deferred clinical materials | | | - | | | - | | | - |
| Total current assets | | | 32,487,038 | | | 4,631,390 | | | 37,118,428 |
| Total assets | | $ | 32,487,038 | | $ | 4,631,390 | | $ | 37,118,428 |
| Liabilities and Stockholders' Equity | | | | | | | | | |
| Current liabilities: | | | | | | | | | |
| Accounts payable | | $ | 1,845,705 | | $ | | | $ | 1,845,705 |
| Accrued expenses | | | 680,830 | | | | | | 680,830 |
| Total current liabilities | | | 2,526,535 | | | - | | | 2,526,535 |
| Total liabilities | | $ | 2,526,535 | | $ | - | | $ | 2,526,535 |
| Commitments and contingencies (Note 7) | | | | | | | | | |
| Stockholders' equity: | | | | | | | | | |
| Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding | | | - | | | | | | - |
| Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively | | | 816 | | | | | | 816 |
| Additional paid-in capital | | | 80,919,684 | | | | | | 80,919,684 |
| Accumulated deficit | | | (50,959,997) | | | 4,631,390 | | | (46,328,607) |
| Total stockholders' equity | | | 29,960,503 | | | 4,631,390 | | | 34,591,893 |
| Total liabilities and stockholders' equity | | $ | 32,487,038 | | $ | 4,631,390 | | $ | 37,118,428 |

16

Table of Contents

| | | | | | | | | | |
| | | Three Months Ended September 30, 2022 |
| | | as | | Restatement | | As |
| | | Reported | | Impacts | | Restated |
| Operating expenses: | | | | | | | | | |
| Research and development | | $ | 5,313,033 | | $ | (1,189,495) | | $ | 4,123,538 |
| General and administrative | | | 2,361,299 | | | - | | | 2,361,299 |
| Total operating expenses | | | 7,674,332 | | | (1,189,495) | | | 6,484,837 |
| | | | | | | | | | |
| Operating loss | | | (7,674,332) | | | 1,189,495 | | | (6,484,837) |
| Other income: | | | | | | | | | |
| Interest income | | | 52,886 | | | - | | | 52,886 |
| Grant Income | | | | | | | | | |
| Total other income | | | 52,886 | | | - | | | 52,886 |
| | | | | | | | | | |
| Loss before income taxes | | | (7,621,446) | | | 1,189,495 | | | (6,431,951) |
| Income tax expense (benefit) | | | - | | | - | | | - |
| Net loss | | $ | (7,621,446) | | $ | 1,189,495 | | $ | (6,431,951) |
| Basic and diluted loss per common share | | $ | (0.93) | | | - | | $ | (0.79) |
| Weighted average number of common shares outstanding, basic and diluted | | | 8,163,923 | | | - | | | 8,163,923 |

| | | | | | | | | | |
| | | Nine Months Ended September 30, 2022 |
| | | As | | Restatement | | As |
| | | Reported | | Impacts | | Restated |
| Operating expenses: | | | | | | | | | |
| Research and development | | $ | 14,938,532 | | $ | (4,631,390) | | $ | 10,307,142 |
| General and administrative | | | 7,403,817 | | | - | | | 7,403,817 |
| Total operating expenses | | | 22,342,349 | | | (4,631,390) | | | 17,710,959 |
| | | | | | | | | | |
| Operating loss | | | (22,342,349) | | | 4,631,390 | | | (17,710,959) |
| Other income: | | | | | | | | | |
| Interest income | | | 108,559 | | | - | | | 108,559 |
| Grant Income | | | | | | | | | |
| Total other income | | | 108,559 | | | - | | | 108,559 |
| | | | | | | | | | |
| Loss before income taxes | | | (22,233,790) | | | 4,631,390 | | | (17,602,400) |
| Income tax expense (benefit) | | | - | | | - | | | - |
| Net loss | | $ | (22,233,790) | | $ | 4,631,390 | | $ | (17,602,400) |
| Basic and diluted loss per common share | | $ | (2.72) | | | - | | $ | (2.16) |
| Weighted average number of common shares outstanding, basic and diluted | | | 8,161,787 | | | - | | | 8,161,787 |

17

Table of Contents

| | | | | | | | | |
| | | Nine Months Ended September 30, 2022 |
| | | As | | Restatement | | As |
| | | Reported | | Impacts | | Restated |
| Cash flows from operating activities: | | | | | | | | |
| Net loss | | $ | (22,233,790) | | 4,631,390 | | $ | (17,602,400) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
| Stock-based compensation expense | | | 7,694,716 | | - | | | 7,694,716 |
| Changes In operating assets and liabilities: | | | | | | | | |
| Prepaid expenses and other current assets | | | (184,483) | | (4,631,390) | | | (4,815,873) |
| Accounts payable | | | 1,157,631 | | - | | | 1,157,631 |
| Accrued expenses | | | (137,610) | | - | | | (137,610) |
| Net cash used in operating activities | | | (13,703,536) | | - | | | (13,703,536) |
| Cash flows from financing activities: | | | | | | | | |
| Proceeds from exercise of stock options | | | 4,613 | | - | | | 4,613 |
| Net cash used in financing activities | | | 4,613 | | - | | | 4,613 |
| Net (decrease) increase in cash and cash equivalents | | | (13,698,923) | | - | | | (13,698,923) |
| Cash and cash equivalents, beginning of period | | | 45,686,014 | | - | | | 45,686,014 |
| Cash and cash equivalents, end of period | | $ | 31,987,091 | | - | | $ | 31,987,091 |

(12) Subsequent Events

On October 31, 2023, the Company entered into an Underwriting Agreement (the "Underwriting Agreement") with Canaccord Genuity LLC relating to the sale of 1,250,000 units consisting of (i) one share of its common stock and (ii) an accompanying warrant (each warrant to purchase one share of common stock). The public offering price was $6.00 per unit.

Each common stock warrant sold with the shares of common stock represents the right to purchase one share of our common stock at an exercise price of $9.00 per share, and redeemable at the Company's option, in whole or in part, at a redemption price equal to $0.001 per warrant upon 30 days' prior written notice, at any time after (i) the Company's public announcement of Positive Topline Data (as defined in the Warrant Agreement) from its Phase 3 pivotal study in patients with Parkinson's Disease and (ii) the date on which (a) the closing price of the Company's common stock on the principal exchange or trading facility on which it is then traded has equaled or exceeded $14.25 and (b) the average daily trading value (ADTV) of The Company's common stock is equal to or exceeds $2,000,000, for two consecutive Trading Days. The common stock warrants are exercisable immediately and will expire on November 2, 2028, five years from the date of issuance. The net proceeds from the offering were approximately $6,766,000, after deducting underwriting discounts and commissions and estimated offering expenses, and excluding the exercise of any warrants.

.

17

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," "will," or "would," and or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

| | ● | our cash and cash equivalents balance, runway and needs as well as financing plans; |
| | ● | our business strategies; |
| | ● | the timing of regulatory submissions; |
| | ● | our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; |
| | ● | risks relating to the timing and costs of clinical trials and the timing and costs of other expenses; |
| | ● | risks related to market acceptance of products; |
| | ● | risks associated with our reliance on third-party organizations; |
| | ● | our competitive position; |
| | ● | assumptions regarding the size of the available market, product pricing and timing of commercialization of our product candidates; |
| | ● | our intellectual property position and our ability to maintain and protect our intellectual property rights; |
| | ● | our results of operations, financial condition, liquidity, prospects, and growth strategies; |
| | ● | our cash needs and financing plans; |
| | ● | the industry in which we operate; and |
| | ● | the trends that may affect the industry or us. |

You should refer to Part I, Item 1A "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Those factors are updated, as applicable, in "Factors that May Affect Future Results" below. As a result of the risks, uncertainties and assumptions described above and elsewhere, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the

18

Table of Contents

significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by law.

The following Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with: (i) the interim financial statements and related notes thereto which are included in this Quarterly Report on Form 10-Q; and (ii) our annual financial statements for the year ended December 31, 2023 which are included in our Annual Report on Form 10-K for the year ended December 31, 2022.

Restatement of Previously Issued Consolidated Financial Statements

As disclosed in our Annual Report on Form 10-K filed with the SEC on March 31, 2023.during our preparation of our 2022 audited combined financial statements and notes thereto, we concluded that there were material research and development expenses and related balance sheet errors in its previously issued unaudited condensed financial statements as of and for each of the quarterly and year to date periods ended March 31, 2022, June 30, 2022 and September 30, 2022, primarily relating to the timing of payments for research and development expenses and recognition of expenses.
2023.


See Note 12 - Restatement of Previously Issued Unaudited Condensed Financial Statements, to the Financial Statements in the Form 10-K for additional information related to the restatements.

Company Overview

We are a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease ("AD") and Parkinson's disease ("PD"). We are developing our lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, Buntanetap was observed to inhibit the synthesis of neurotoxic proteins - APP/Aβ ("APP"), tau/phospho-tau ("tau") and α-Synuclein ("αSYN") - that are one of the main causes of neurodegeneration. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. We have observed in our clinical studies in early AD and early PD patients and pre-clinical studies in mice and rats that Buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function.

In 2021, we completed two Phase 1/2 clinical studies: one in 14 early AD patients, and one in 54 early PD patients (together, the "AD/PD Trials"). In the AD/PD Trials, early AD patients were defined as those with a Mini Mental State Examination ("MMSE") score between 19 and 28 and early PD patients as those patients at Hoehn & Yahr stages 1, 2 or 3. MMSE is a brief screening instrument used to assess cognitive function, with total scores ranging from 0 to 30 and a lower score indicating greater disease severity, while the Hoehn & Yahr scale is a medical assessment used to measure staging of the functional disability associated with PD, where a higher stage indicates greater disease severity. In collaboration with the Alzheimer's Disease Cooperative Study ("ADCS"), we also conducted a trial in 16 early AD patients (the "ADCS Trial"). In the ADCS Trial, early AD patients were defined as those patients with a MMSE score between 19 and 28. All three clinical trials were double-blind, placebo-controlled studies. We designed the studies by applying our understanding of the underlying neurodegenerative disease states, and measured efficacy as well as both target and pathway engagement both target and pathway validation in the spinal fluid of patients to determine whether patients improvement following treatment. correlated with the CSF biomarkers.improved following treatment. In addition to meeting their primary endpoints of safety and tolerability and secondary endpoint of pharmacokinetics of Buntanetap, our AD/PD Trials met exploratory endpoints of measures of

20

Table of Contents

biomarkers and improvements in cognition in AD patients, and in function in PD patients. We believe that the AD/PD Trials represent the first double-blind placebo-controlled studies that showed improvements in AD patients, as measured by ADAS-Cog, and in PD patients, as measured by UPDRS. Following completion of the AD/PD Trials, we submitted our data to the U.S. Food and Drug Administration ("FDA") and requested direction to further pursue the development of Buntanetap in early PD patients. With the FDA's guidance, we initiated a Phase 3 study in early PD patients in August 2022 (our "Phase 3 PD Study"). In the Phase 3 PD Study, early PD patients were defined as those at Hoehn & Yahr stages 1, 2 or 3 and OFF times of less than two hours per day. OFF time refers to when PD motor and/or non-motor symptoms occur between medication doses. We also submitted a proposed protocol for the treatment of moderate AD to the FDA, and after receiving permission to proceed, we initiated a Phase 2/3 study in mild to moderate AD patients in February 2023 (our "Phase 2/3 AD Study"). In the Phase 2/3 AD Study, mild to moderate AD patients were defined as those with a MMSE score between 14 and 24. At the completion of the ADCS Trial, the data

19

Table of Contents

showed that Buntanetap is a translational inhibitor in humans just like in animals, and we further observed that there was statistical improvement in cognition in early AD patients, just like in the AD/PD Trials.

Our Phase 3 PD Study and Phase 2/3 AD Study each had built in interim analyses. Our Phase 3 PD Study incorporated an interim analysis at two months, the results of which were disclosed on March 31, 2023. The pre-planned interim analysis was conducted by our data analytics provider based on 132 patients from all cohorts collectively for which baseline and two-month data was available. As the interim analysis was conducted at two months of the six-month endpoint and only on 132 patients, it may not be indicative of the results at six months for the full patient population. because as the trial progresses, clinical outcomes may materially change as patient enrollment continues. Based on the results of the interim analysis, we proceeded with the Phase 3 PD Study as planned in accordance with the previously established protocol. The data safety monitoring board (DSMB) also conducted an interim safety analysis and reported that buntanetap was generally well-tolerated and the study should proceed as planned. we remain blinded to the Phase 3 PD Study and We do not have safety or efficacy data from the trial.study was completed on December 4, 2023, and we have been organizing and cleaning data since that date. On May 9, 2024, we announced unblinding of the Phase 3 PD data. We expect to release topline PD Study efficacy data in June 2024.

We disclosed the results of the interim analysis for our Phase 2/3 AD Study was based on 107 patients having completed six weeks of treatment. based on the results of the interim analysis which we disclosed on October 12, 2023, we are proceeding with the Phase 2/3 AD study as planned. without The need to add additional patients. The data safety monitoring board (DSMB) also conducted an interim safety analysis and reported that buntanetap was generally well-tolerated and the study. should proceed as planned.on October 23, 2023, and similar to our PD study, based on the outcome of the interim analysis we proceeded with the study as planned. The Phase 2/3 AD study was completed on February 13, 2024. On April 29, 2024, we announced data from the AD study. We will report the data to the FDA and ask for an end-of-Phase 2 meeting for AD. We expect to discuss the AD data with the FDA in the two to three months following the release and then move on to the next Phase 3 study to confirm and expand these findings in an 18-month disease-modifying trial, focusing on biomarker-positive early AD patients. We further plan to present the data at AAIC 2024 and to publish it in a peer-reviewed journal.

We plan to consult with the FDA following completion of both studies, to obtain feedback on our additional AD and PD studies, including conducting an open label extension study following the completion of the initial trials. Using the data from the Phase 3 PD Study, we intend to design an 18-month long disease-modifying Phase 3 study in the same early PD patients. In addition, we intend to conduct a short 6-month study in advanced PD patients during the second half of the 18-month disease modifying Phase 3 study at which time we will define the advanced PD patient population for the purposes of such study. Similarly, using the data from the Phase 2/3 AD Study interim analysis, we intend to design an 18-month disease modifying Phase 3 study in the same early AD patient population. In addition, We intend to conduct a short 6-month study in advanced AD patients during the second half of the 18-month disease modifying Phase 3 study, at which time we will define the advanced AD patient population for the purposes of such study. We expect both the ongoing Phase 3 PD Study and the Phase 2/3 AD Study to be completed by the end of 2023, and we intend to announce the data from the final analyses in the first quarter of 2024.


By the end of 2026, our goal is to have conducted the required pivotal studies for Buntanetap to be able to file two new drug applications ("NDAs") with the FDA.

We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving brain function, our goal is to treat memory loss and dementia associated with AD, as well as body and brain function associated with PD. Based on pre-clinical and clinical data collected to date, we believe that Buntanetap has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration, potentially enabling Buntanetap to be the only drug to improve cognition in AD and motor function in PD. The industry has encountered challenges in specifically targeting one neurotoxic protein, be it APP, tau or αSYN, indicating that doing

21

Table of Contents

so does not change the course of neurodegeneration. Our goal is to develop a disease modifying drug ("DMD") for patients with neurodegeneration by leveraging our clinical and pre-clinical data to inhibit the three most relevant neurotoxic proteins. Studies have found that AD and PD are the most common neurodegenerative diseases in the U.S. and accordingly, these diseases present two unmet needs of the aging population and two potentially large U.S. markets if a DMD is developed and approved.

Funding Requirements

We have never been profitable and have incurred net losses since inception. Our accumulated deficit at March 31, 2024 was $111,326.0 thousand. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.

We do not have sufficient capital on hand to fund our operations for the next 12 months and will need to raise additional capital to meet our obligations as they become due. We believe that actively managing our cash and working capital as of March 31, 2024, as well as the additional $0.8 million of proceeds received under our ELOC Purchase Agreement during May 2024, will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2024. We will need to raise substantial additional capital to complete the development and commercialization of our product candidates through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. However, there can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. If we

20

Table of Contents

are unable to raise sufficient additional capital or defer sufficient operating expenses, we may be compelled to reduce the scope of our operations.

In order to fund operations and additional clinical trials, we plan to finance our cash needs through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. We have no committed external sources of funds other than our ELOC facility, which was announced on April 25, 2024. Additional equity or debt financing or collaboration and licensing arrangements may not be available on acceptable terms, if at all.

Results of Operations

Operating expenses and other income were comprised of the following:

| | | | | | | |
| | | Three Months Ended || Nine Months Ended | |
| | | September 30, | | September 30, | |
| | | March 31, |
| | | 2023 | | 2022 | | 2023 || 2022 | |
| | | 2024 | | 2023 |
| |
| | | (in thousands) || (in thousands) | |
| Operating expenses: | | | | | | |
| Research and development | | $ | 13,837.7 | | $ | 4,123.5 | | $ | 29,885.9 | | $ | 10,307.1 | |6,514.9 | | $ | 7,786.1 |
| General and administrative | | $ | 1,025.6 | | $ | 2,361.3 | | $ | 4,706.8 | | $ | 7,403.8 | |1,294.9 | | $ | 2,183.7 |
| Other income: | | | | | | |
| Change in fair value of warrants | | | 6,698.7 | | | - |
| | | | | | |
| Interest income | | $ | 146.7 | | $ | 52.9 | | $ | 601.8 | | $ | 108.6 | |
| Interest income | | $ | 44.2 | | $ | 232.5 |

Three Months Ended September 30, 2023 and 2022
Three Months Ended March 31, 2024 and 2023

Research and Development Expenses

Research and development expenses decreased by $1,271.2 thousand for the three months ended March 31, 2024, compared to the prior year period. The increase was primarily the result of an increase of $10,006.8 thousand in clinical expenses related This decrease was primarily the result of a net decrease of $980.9 thousand in contract research expenditures, driven by timing of study costs with respect to our Phase 3 study in early PD patients and Phase 2/3 in AD patients. an increase of $291.3 thousand in contract research expenses, partially offset by a decrease of $475.4 Additionally, there was a decrease of $644.2 thousand in stock-based compensation expense We expect research and development expenses in 2023 will be higher than the prior year as we continue our Phase 3 study in early PD patients and our Phase 2/3 study in moderate AD patients.compared to the prior year period, driven by lower fair values being amortized in 2024 as compared to 2023, as a result of lower stock price. These decreases were partially offset by increases in employee related costs, due primarily to additional headcount in 2024, compared to the same period in 2023.

General and Administrative Expenses

General and administrative expenses decreased by $888.8 thousand for the three months ended March 31, 2024, compared to the prior year period. The decrease was primarily the result of a decrease of $533.4 thousand in stock-based compensation expense, driven by lower fair values being amortized in 2024 as compared to 2023, as a result of lower stock price. Additionally, there was a decrease of $385.1 thousand in professional fees a decrease of $81.4 in administrative expenses and a decrease of $58.0 in insurance expense, partially offset by an increase of $45.5 in salary expense.

Other Income

Other income increased $93.8 thousand for the three months ended September 30, 2023 compared to the prior year period, The increase was primarily the result of higher return on investment compared to the prior year period.as a result of lower legal and investor relations costs incurred during the first quarter.

22

Change in Fair Value of Warrants

Nine Months Ended September 30, 2023 and 2022

Research and Development Expenses

Research and development expenses increased by $19,578.7 thousand for the nine months ended September 30, 2023 compared to Change in fair value of warrants was a gain of $6,698.7 thousand for the three months ended March 31, 2024, as compared to zero for the prior year period. This increase was primarily the result of an increase of $20,305.1 thousand in clinical expenses related to our Phase 3 study in early PD patients, Phase 2/3 in AD patients, and an increase in salary expense of 384.6, partially offset by decrease of $482.7 thousand for the cost of materials and a decrease of $688.0 thousand in stock-based compensation expense. We expect research and development expenses in 2023 will be higher than the prior year as we continue our Phase 3 study in early PD patients and our Phase 2/3 study in moderate AD patients.attributable to the fair value remeasurement with respect to our liability-classified Canaccord Warrants during the first quarter of 2024. The associated gain recorded in Results of Operations was primarily driven by the decrease in our stock price during the first quarter of 2024, which caused the fair value of the liability to decrease substantially.

General and Administrative Expenses

General and administrative expenses decreased by $2,697.0 thousand for the nine months ended September 30, 2023 compared to the prior year period. the decrease was primarily the result of a decrease of $3,260.7 thousand in stock-based compensation expense, partially offset by an increase of $552.3 thousand in professional fees.


21

Table of Contents

Interest Income

Other income increased $493.2 thousand for the nine months ended September 30, 2023 Interest income decreased $188.3 thousand for the three months ended March 31, 2024 compared to the prior year period. The increase was primarily the result of higher return on invested funds This decrease was primarily the result of lower cash and cash equivalent balances when compared to the prior year period.

Liquidity and Capital Resources

Since our inception in 2008, we have devoted most of our cash resources to research and development and general and administrative activities. We have financed our operations primarily with the proceeds from the sale of common stock, redeemable convertible preferred stock and convertible promissory notes and funding from research grants. stock and warrants. To date, we have not generated any revenue from the sale of products, and we do not anticipate generating any revenue from the sale of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of March 31, 2024, our principal source of liquidity was our cash and cash equivalents, which totaled $3,137.0 thousand.

Cash Flows

The following table summarizes our cash flows from operating, investing and financing activities:

| | | | | | | | |
| | | Three Months Ended ||
| | | March 31, |
| | | 2024 | | 2023 |
| |
| | | (in thousands) | |
| Statement of Cash Flows Data: | | | | | | | |
| Total net cash provided by (used in): | | | | | | ||
| Operating activities | | $ | (30,602.3) | | $ | (13,703.5) | |
| Operating activities | | $ | (7,032.8) | | $ | (11,626.3) |
| Financing activities | | | 4,415.0 | | | 7.4 |
| Net (decrease) in cash and cash equivalents | | $ | (2,617.8) | | $ | (11,618.9) |

Operating Activities

For the nine months ended September 30, 2023, cash used in operations increased $16,898.8 For the three months ended March 31, 2024, cash used in operations decreased $4,593.5 thousand compared to the same period in the prior year. The decrease in cash used in operations was primarily the result of a decrease in cash paid for clinical trial expenses

given the planned timing of study costs and related disbursements.

Contingent upon continued achievement of our fundraising objectives,

we expect cash used in operating activities to increase in 2023 as compared to 2022 due to an expected increase in our continue to be elevated during and after 2024 due to expected operating losses associated with ongoing development of our product candidates, including clinical trial expenses for our planned Phase 3 trial in early PD patients and a second clinical trial in early AD patients.additional studies in early PD patients and a next Phase 3 study in AD patients.

Financing Activities

For the three months ended March 31, 2024, cash provided by financing activities during the nine months ended September 30, 2023 was due to $8,571.2 thousand in proceeds from the sale of common stock and $8.4 thousand in proceeds from the exercise of stock options.increased by $4,407.6 thousand due primarily to proceeds from the issuance of common stock and the exercise common stock warrants. In the prior year period, there were amounts provided by financing activities solely with respect to minor stock option exercise proceeds.

On October 31, 2023, the Company, entered into an Underwriting Agreement (the "Underwriting Agreement") with Canaccord Genuity LLC relating to the sale of 1,250,000 units consisting of (i) one share of its common stock and (ii) an accompanying warrant (each warrant to purchase one share of common stock). the public offering price was $6.00 per unit. Each common stock warrant sold with the shares of common stock represents the right to purchase one share of our common stock at an exercise price of $9.00 per share, and redeemable at the Company's option in whole or in part, at a redemption price equal to $0.001 per warrant upon 30 days' prior written notice, at any time after (i) the Company's public announcement of Positive Topline Data (as defined in the Warrant Agreement) from its Phase 3 pivotal study in patients with Parkinson's Disease and (ii) the date on which (a) the closing price of the Company's common stock on the principal exchange or trading facility on which it is then traded has equaled or exceeded $14.25 and (b) the average daily trading value (ADTV) of the Company's common stock is equal to or exceeds $2,000,000, for two consecutive Trading Days. The common stock warrants are exercisable immediately and will expire on November 2, 2028, five years from the date of issuance. The net proceeds.from the offering were approximately $6,766,000, after deducting underwriting discounts and commissions and estimated offering expenses, and excluding the exercise of any warrants.

Funding Requirements

We do not have sufficient capital on hand to fund our operations for the next 12 months and will need to raise additional capital to meet our obligations as they become due. We believe that our current cash and cash equivalents and funding from existing grants will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2024, including our ongoing Phase 2/3 AD Trial and our ongoing Phase 3 PD Trial. We will need to raise substantial additional capital to complete the development and commercialization of our product candidates through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. However, there can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. We have no committed external sources of funds. If we are unable to raise sufficient additional capital or defer sufficient operating expenses, we may be compelled to reduce the scope of our operations.
22

In order to fund operations and additional clinical trials, we plan to finance our cash needs through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. We have no committed external sources of funds. Additional equity or debt financing or collaboration and licensing arrangements may not be available on acceptable terms, if at all.
Table of Contents

Contractual Obligations and Other Commitments

This item is not required for smaller reporting companies.

Factors that May Affect Future Results

You should refer to Part I, Item 1A "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 for a discussion of important factors that may affect our future results.

24

Table of Contents

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined by applicable SEC regulations.

Discussion of Critical Accounting Policies and Significant Judgments and Estimates

The preparation of financial statements in conformity with GAAP requires us to use judgment in making certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in our financial statements and accompanying notes. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require difficult, subjective and complex judgments by Management in order to make estimates about the effect of matters that are inherently uncertain. During the three month period ended March 31, 2024, there were no significant changes to our critical accounting policies from those described in our annual financial statements for the year ended December 31, 2023, which we included in our Annual Report on Form 10-K for the year ended December 31, 2023.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

This item is not required for smaller reporting companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our Management, with the participation of our principal executive officer who is also our interim principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and Management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our principal executive officer/interim principal financial officer has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were not effective due to the material weakness in our internal control over financial reporting described below,effective to ensure that the information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our Management, including our principal executive officer/interim principal financial officer, to allow timely decisions regarding required disclosure.

Identified Material Weakness

In connection with the audit of our financial statements as of December 31, 2022 and 2021 and for the years ended December 31, 2022 and 2021, we identified a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness related to the proper classification of research and development expenses, which impacted our previously issued condensed financial statements as of and for the three months ended March 31, 2022, three and six months ended June 30, 2022 and three and nine months ended September 30, 2022.

Remediation Plan

Our management, with the oversight of the Audit Committee of the Board of Directors, has updated our internal processes and controls to strengthen their effectiveness and developed a remediation plan which includes the following actions:

25

Table of Contents

| | ● | Enhance our review procedures over significant contracts with contract manufacturing organizations and contract research organizations; |
| | ● | Augment existing staff; and |
| | ● | Strengthen the review process. |

We will not be able to conclude whether the actions we are taking will fully remediate the material weakness in our internal control over financial reporting until the updated controls have operated for a sufficient period of time and management has concluded, through testing, that such controls are operating effectively. We may also conclude that additional measures may be required to remediate the material weakness in our internal control over financial reporting, which may necessitate further action.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(f) and 15d-15(f) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.except for the initiation of our remediation efforts with respect to the material weakness relating to our internal control over financial reporting described above. We have taken actions to remediate the material weakness, which has resulted and may continue to result in changes in our internal control over financial reporting in periods subsequent to March 31, 2023 as we continue to address this material weakness.

23

Table of Contents

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.

Item 1A. Risk Factors

Risk factors that may affect our business and financial results are discussed within Item 1A "Risk Factors" of our annual report on Form 10-K filed with the SEC on March 29, 2024 ("2023 Form 10-K"). There have been no material changes to the disclosures relating to this item from those set forth in our 2023 Form 10-K.
this item is not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

24

Table of Contents

Item 6. Exhibits

| | | |
| Exhibit | | Description of Exhibit |
| Number | | |
| | | |
| 3.1 | | Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit 3.1 to Form 8-K filed February 6, 2020.) |
| | | |
| 3.2 | | Amended and Restated Bylaws of the Registrant. (Incorporated by reference to Exhibit 3.2 to Form 8-K filed February 6, 2020.) |
| | | |
| 31.1 | | Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| | | |
| 31.2 | | Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| | | |
| 32.1 | | Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| | | |
| 32.2 | | Certification Pursuant to Section 906 302 of the Sarbanes-Oxley Act of 2002. |

| | | |
| 101.INS | | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| | | |
| 101.SCH | | Inline XBRL Taxonomy Extension Schema Document |
| | | |
| 101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| | | |
| 101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| | | |
| 101.LAB | | Inline XBRL Taxonomy Extension Labels Linkbase Document |
| | | |
| 101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| | | |
| 104 | | Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |

25

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| Signature | | Title | | Date |
| | | | | |
| /s/ Maria Maccecchini | | President and Chief Executive Officer (Principal | | May 10, 2024 |
| Maria Maccecchini | | Executive Officer | | |
| | | | | |
| /s/ Henry Hagopian III | | Chief Financial Officer) (principal financial and | | November 8, 2023 |
and Interim Principal Financial Officer) | | |
| Henry Hagopian III | | accounting officer) | | |
| | | | | |

26

Exhibit 31.1

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),
AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Maria Maccecchini, certify that:

| | 1. | I have reviewed this Quarterly Report on Form 10-Q of Annovis Bio, Inc.; |
| | 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| | 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| | 4. | The registrant's other certifying officer and I are I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| | (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared; |
| | (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| | (c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| | (d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
| | 5. | The registrant's other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
| | (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
| | (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
| | |
| Date: May 10, 2024 | /s/ Maria Maccecchini |
| | Maria Maccecchini |
| | President and Chief Executive Officer |
Exhibit 31.2

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Henry Hagopian III, certify that:

| | 1. | I have reviewed this Quarterly Report on Form 10-Q of Annovis Bio, Inc.; |

| | (Principal Executive Officer and Interim Principal Financial Officer) |
| | 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| | 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| | 4. | The registrant's other certifying Officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| | (a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| | (b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| | (c) | evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| | (d) | disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
| | 5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
| | (a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
| | (b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |

| | |
| Date: November 8, 2023 | /s/ Henry Hagopian III |
| | Henry Hagopian III |
| | Chief Financial Officer) |


Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED

PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Annovis Bio, Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Maria Maccecchini, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

| | 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| | 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. |
| | |
| Date: May 10, 2024 | /s/ Maria Maccecchini |
| | Maria Maccecchini |
| | President and Chief Executive Officer |
Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Annovis Bio, Inc. (the "Company") on Form 10-Q for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Henry Hagopian III, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

| | 1. | the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |

| | (Principal Executive Officer and Interim Principal Financial Officer) |
| | 2. | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |

| | |
| Date: November 8, 2023 | /s/ Henry Hagopian III |
| | Henry Hagopian III |
| | Chief Financial Officer) |